Navigation Links
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Date:8/19/2007

nosed in the U.S. annually, with the number increasing over the past 20-30 years. Carcinoid tumors that metastasize to the liver have a poor prognosis. Traditionally, chemotherapy relieves symptoms in less than 30% of cases of metastatic carcinoid tumors, usually for less than 1 year. Carcinoid tumors typically produce a condition called "carcinoid syndrome" which is caused by the release of hormones by the tumors into the blood stream. The symptoms vary depending on which hormones are released by the tumors, but typically include diarrhea, facial flushing, wheezing, abdominal pain and valvular heart disease.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and gastrointestinal diseases. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs in pre-clinical development for other significant health care markets, including gastrointestinal disorders. One of the Company's lead drug candidates, Atiprimod is presently in a Phase II clinical trial in advanced carcinoid cancer patients, a neuroendocrine tumor, and in a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients. Another anti-cancer drug, L-Annamycin, is being developed as a treatment for forms of relapsed or refractory acute leukemia, a currently incurable blood cancer. L-Annamycin is currently in a Phase I clinical trial in adult relapsed or refractory acute lymphocytic leukemia, and in a Phase I clinical trial in children and young adults with refractory or relapsed acute lymphocytic leukemia or acute myelogenous leukemia. L- Annamycin, a member of the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including potential activity against multi- drug resistant tumors and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Russia,s ... The Pharma 2020 Strategy provides incentives for local producers ... and foreign markets. These trends, however, were affected by ... following political and economic sanctions imposed on ... Russia responded to the ...
(Date:9/16/2014)... 2014 Research and Markets ... Laparoscopy Devices Industry Report 2014" report to ... Devices Industry Report 2014 is a professional and ... global laparoscopic devices. The report provides ... classifications, applications and industry chain structure. The laparoscopic ...
(Date:9/16/2014)... Sept. 16, 2014 Based on its ... Frost & Sullivan recognises Incisive Surgical with the ... Value Leadership. Incisive Surgical,s uniquely-designed, innovative INSORB® Absorbable ... eliminates the need for patients to undergo the ... removal  that may result in increased pain, wound ...
Breaking Medicine Technology:Global Medicines for Russia 2Global Laparoscopy Devices Industry Report 2014 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 3Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 4Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 5
(Date:9/16/2014)... (PRWEB) September 16, 2014 Transparency Market ... that the global facial care market is expected to ... The report, titled ‘Facial Care Market (By Product Type ... Wash, Cleansing Wipes, Serums and Masks and Others (fade ... Share, Growth, Trends and Forecast 2013 – 2019,’ is ...
(Date:9/16/2014)... 2014 Whatisfinalexpenseinsurance.com has released a ... affordable life insurance for seniors. , Finding affordable life ... A big part of the insurance market has moved ... tips that clients can use when shopping for life ... is important for providing financial security for vulnerable family ...
(Date:9/16/2014)... is effective in diagnosing concussion-related brain disease while a ... conducted at the Icahn School of Medicine at Mount ... Haven, and published September 16 in the journal ... that an experimental radiolabeled compound called [18 F]-T807, which ... that accumulates in the brain with repetitive blows to ...
(Date:9/16/2014)... Researchers at the Hebrew University of Jerusalem have ... at coaxing adult cells to become quality pluripotent ... and expanding area that aims to replace lost ... transplantation. Because stem cells derived from human embryos ... reprogramming adult cells back to an embryo-like state ...
(Date:9/16/2014)... Gary F. Locke, the former U.S. Ambassador to ... Group for exclusive representation of his global speaking activities. ... of Washington, Locke is widely recognized as one of ... and business growth. , “Gary Locke provides audiences with ... an organization’s global presence in and with China,” stated ...
Breaking Medicine News(10 mins):Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3Health News:Life Insurance for Seniors - Clients Can Find Fast Life Insurance By Comparing Online Quotes! 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 3Health News:Scientists create therapy-grade stem cells using new cocktail to reprogram adult cells 2Health News:Gary Locke, Former Ambassador to China, Selects Worldwide Speakers Group for Exclusive Lecture Representation 2
... cells in the human brain is linked to learning and ... Florida. The research is the first to show such a ... upcoming print issue of the journal Brain , provide ... and reveal potential cellular targets for drug therapy. The ...
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- ... 2008, nearly one in four American parents with health insurance ... to access the medical care their children needed. Parents ... likely than others to say their insurance coverage did not ...
... Despite the fact that an estimated 25 million ... general anesthesia, scientists have only been able to hypothesize ... They previously thought that the processes of "going under" ... the same way. Now, researchers at the University of ...
... Va.SNM supports the U.S. Senate in its introduction of ... and Radiation Therapy Act of 2010 (CARE Act), S. ... by Sen. Mike Enzi [R-WY], aims to ensure that ... are set at the state level. The bill,s co-sponsors ...
... Melissa Lee Phillips HealthDay Reporter , WEDNESDAY, Aug. ... to an inheritable eye disease that affects 5 percent of ... for transplants of the cornea. The genetic disorder, ... the cornea -- the thin, clear membrane that covers the ...
... Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- U.S. ... U.S. judge to halt any expansion of stem cell ... basically blindsided the scientific community, effectively takes embryonic stem ... when then-President George W. Bush ordered that federal monies ...
Cached Medicine News:Health News:Scientists find link in humans between nerve cell production, memory 2Health News:Scientists find link in humans between nerve cell production, memory 3Health News:Even Before Recession, 14 Million Kids 'Underinsured': Study 2Health News:Even Before Recession, 14 Million Kids 'Underinsured': Study 3Health News:Penn study sheds light on how the brain shifts between sleep/awake states under anesthesia 2Health News:SNM applauds US Senate's introduction of CARE Act 2Health News:Study Links Gene to Serious Eye Disease 2Health News:Obama to Appeal Stem Cell Ruling 2Health News:Obama to Appeal Stem Cell Ruling 3
...
Liquichek Elevated CRP Control is a liquid assayed serum control with elevated levels of C-Reactive Protein....
LiquichekCardiac Markers Plus Control LT is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Liquichek Cardiac Markers Plus Control is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Medicine Products: